You are not logged in.
Please login to continue selecting trials.
Trial Information
Generic NameRisperidoneProduct NameRISPERDAL®Therapeutic AreaBehaviors and Mental DisordersEnrollment246% FemaleN/A% WhiteN/A
Product ClassAtypical AntipsychoticsSponsor Protocol NumberRIS-USA-72Data PartnerJohnson & JohnsonCondition StudiedSchizophreniaMean/Median Age (Years)N/A
Supporting Documentation
- Data Definition Specification Available
- Protocol with Amendments Available
- Analysis Datasets Available
- Clinical Study Report Available
Approved Data Requests Associated with this Trial
- 2024-0008 : Sex differences in antipsychotic efficacy and side-effects in adults with acute exacerbations of schizophrenia: an individual-participant network meta-analysis
- 2022-4992 : Temporal trajectories of side-effects associated with antipsychotic treatment ? An individual participant data meta-analysis
- 2021-4754 : Harnessing clinical trial data to inform real-world clinical decision making in the treatment of schizophrenia
- 2021-4575 : A NOVEL METHOD TO SUMMARIZE SAFETY IN CLINICAL TRIALS USING PHARMACOLOGICAL CLASS-RELATED RISKS IN FAERS
- 2019-3978 : Safety of Risperidone and Paliperdone in schizophrenia and bipolar disorder diagnosed patients - a systematic review and meta-analysis
- 2019-3958 : Machine Learning for predicting treatment efficacy and clinical categorizations across mental health disorders.
- 2019-3941 : Factors moderating estimates of antipsychotic efficacy in schizophrenia
- 2019-3827 : Prediction of outcome and adverse events in antipsychotic treatment
- 2017-1846 : Discontinuation symptoms in antipsychotics: Individual patient level analyses of randomized controlled trials
- 2017-1676 : Placebo Effects in Schizophrenia
- 2016-0880 : Incidence of death and other SAEs related to second generation antipsychotic or placebo treatment in RCTs - a systematic review and meta-analysis